Johnson & Johnson

NYSE:JNJ Voorraadrapport

Marktkapitalisatie: US$553.7b

Johnson & Johnson Toekomstige groei

Future criteriumcontroles 2/6

Johnson & Johnson zal naar verwachting groeien in winst en omzet met respectievelijk 8.3% en 6.3% per jaar. De winst per aandeel zal naar verwachting groeien met 8.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 32.5% zijn.

Belangrijke informatie

8.3%

Groei van de winst

8.68%

Groei van de winst per aandeel

Pharmaceuticals winstgroei14.4%
Inkomstengroei6.3%
Toekomstig rendement op eigen vermogen32.47%
Dekking van analisten

Good

Laatst bijgewerkt15 May 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • May 14

JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns

Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.
Narratiefupdate • Apr 24

JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks

The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.
Seeking Alpha • Apr 17

Johnson & Johnson: Why I See Downside Ahead

Summary Johnson & Johnson only slightly raised its 2026 financial guidance. So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my view, this is due to the sharp decline in demand for Stelara, JNJ's former "cash cow" in the immunology franchise. Moreover, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion doesn't meet my expectations, as Caplyta sales grew by only 8.4% quarter-on-quarter to $270 million. Further in this article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Read the full article on Seeking Alpha
Narratiefupdate • Apr 09

JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience

Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
Nieuw narratief • Mar 30

Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution

Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.
Narratiefupdate • Mar 25

JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience

Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
Nieuw narratief • Mar 18

Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability

Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Mar 11

JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty

Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.
Narratiefupdate • Feb 25

JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk

The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.
Narratiefupdate • Feb 10

JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance

Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.
Narratiefupdate • Jan 27

JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward

Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Nieuw narratief • Jan 25

Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory

Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Jan 09

JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward

Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.
Narratiefupdate • Dec 19

JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook

Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.
Narratiefupdate • Dec 05

JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance

The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.
Narratiefupdate • Nov 21

JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance

Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.
Narratiefupdate • Nov 05

JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance

Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.
Narratiefupdate • Oct 22

Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments

Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.

Winst- en omzetgroeiprognoses

NYSE:JNJ - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2028114,77526,12831,56037,35217
12/31/2027107,23324,34529,45134,07323
12/31/2026100,88722,05226,54431,99721
3/29/202696,36221,04017,41322,870N/A
12/28/202594,19326,80419,31324,530N/A
9/28/202592,14925,11918,67924,204N/A
6/29/202590,62722,66116,39723,028N/A
3/30/202589,33121,81018,57424,783N/A
12/29/202488,82114,06618,05924,266N/A
9/29/202487,69614,76719,18725,146N/A
6/30/202486,57616,38219,99524,642N/A
3/31/202485,64817,07218,39623,191N/A
12/31/202385,15913,32617,94022,791N/A
10/1/202383,70312,42115,73720,278N/A
7/2/202382,34812,42214,54719,073N/A
4/2/202377,45810,73016,20720,472N/A
1/1/202379,99016,37017,48821,194N/A
10/2/202284,85517,87917,73921,576N/A
7/3/202288,19717,23619,95023,582N/A
4/3/202294,88019,83019,73323,315N/A
1/2/202278,74017,80119,75823,410N/A
10/3/202191,44617,88022,46126,021N/A
7/4/202189,19017,76722,56426,114N/A
4/4/202184,21415,11520,85324,252N/A
1/3/202182,58414,71420,18923,536N/A
9/27/202080,85616,98618,30721,591N/A
6/28/202080,50315,18517,44320,735N/A
3/29/202082,72917,16619,76423,231N/A
12/29/201982,05915,119N/A23,416N/A
9/29/201981,70614,151N/A23,262N/A
6/30/201981,32516,332N/A22,007N/A
3/31/201981,59314,679N/A22,138N/A
12/30/201881,58115,297N/A22,201N/A
9/30/201881,3821,542N/A22,062N/A
7/1/201880,6841,372N/A22,056N/A
4/1/201878,6931,245N/A21,749N/A
12/31/201776,4501,300N/A21,056N/A
10/1/201774,36115,827N/A21,604N/A
7/2/201772,53116,335N/A20,699N/A
4/2/201772,17416,505N/A19,491N/A
1/1/201771,89016,540N/A18,767N/A
10/2/201671,59515,941N/A17,199N/A
7/3/201670,87715,027N/A17,978N/A
4/3/201670,18215,546N/A18,886N/A
1/3/201670,07415,409N/A19,569N/A
9/27/201570,51714,715N/A18,849N/A
6/28/201571,88216,106N/A17,363N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei JNJ ( 8.3% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van JNJ ( 8.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.8% per jaar).

Hoge groeiwinsten: De winst van JNJ zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van JNJ ( 6.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.6% per jaar).

Hoge groei-inkomsten: De omzet van JNJ ( 6.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen JNJ zal naar verwachting over 3 jaar hoog zijn ( 32.5 %)

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/20 11:15
Aandelenkoers aan het einde van de dag2026/05/20 00:00
Inkomsten2026/03/29
Jaarlijkse inkomsten2025/12/28

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Johnson & Johnson wordt gevolgd door 53 analisten. 23 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
David ToungArgus Research Company
Matthew MiksicBarclays
Lee HambrightBernstein